Critical Review: Mangoceuticals (MGRX) versus Its Rivals

Mangoceuticals (NASDAQ:MGRX) is one of 18 publicly-traded companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it weigh in compared to its rivals? We will compare Mangoceuticals to related companies based on the strength of its earnings, valuation, profitability, analyst recommendations, risk, institutional ownership and dividends.

Earnings and Valuation

This table compares Mangoceuticals and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Mangoceuticals	$866,792.00	-$9.21 million	-5.74
Mangoceuticals Competitors	$2.39 billion	$82.32 million	13.77

Mangoceuticals’ rivals have higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current recommendations for Mangoceuticals and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	0	0	0	0	N/A
Mangoceuticals Competitors	36	288	416	146	2.76

As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 13.74%. Given Mangoceuticals’ rivals higher probable upside, analysts plainly believe Mangoceuticals has less favorable growth aspects than its rivals.

Insider and Institutional Ownership

56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 61.8% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by institutional investors. 39.3% of Mangoceuticals shares are held by company insiders. Comparatively, 27.3% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Mangoceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Comparatively, Mangoceuticals’ rivals have a beta of 3.97, indicating that their average share price is 297% more volatile than the S&P 500.

Profitability

This table compares Mangoceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-1,053.93%	-243.34%	-200.73%
Mangoceuticals Competitors	-816.62%	-48.14%	-36.60%

Summary

Mangoceuticals rivals beat Mangoceuticals on 9 of the 10 factors compared.

About Mangoceuticals

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.